liposomal irinotecan + raltitrexed + fruquintinib

liposomal irinotecan + raltitrexed + fruquintinib is a combination chemotherapy and targeted therapy regimen being investigated for the treatment of advanced colorectal cancer. The regimen is primarily being developed by The First Affiliated Hospital of the University of Science and Technology of China. It consists of three active agents: liposomal irinotecan, a nanoparticle-encapsulated topoisomerase I inhibitor that induces DNA damage; raltitrexed, a quinazoline folate analogue that acts as a potent and specific inhibitor of thymidylate synthase, thereby disrupting DNA synthesis; and fruquintinib, a highly selective small-molecule inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, which blocks tumor angiogenesis. This triplet combination is designed to provide a multi-pronged attack on tumor cells by simultaneously inhibiting DNA replication and the formation of new blood vessels, particularly in patients who have progressed on standard therapies.

Other names

Fruquintinib plus Liposomal Irinotecan and Raltitrexed